33 results about "Glutaredoxin" patented technology

The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR with Ki of 0.14 μM and 0.46 μM, respectively. E. coli mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains. Two major pathogenic bacteria, which previously had not been known to be sensitive to ebselen, Mycobacterium tuberculosis (tuberculosis) and Helicobacter pylori (stomach ulcer and cancer), were shown to be excellent targets. Helicobacter pylori was also sensitive to ebsulfur.

The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and / or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and / or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and / or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.

The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and / or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and / or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and / or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.

The invention provides recombinant buckwheat glutaredoxin as well as a preparation method and application thereof. The preparation method comprises the steps of constructing the recombinant buckwheat glutaredoxin (rbGrx) onto a pGEX-6p-1 carrier, transforming into escherichia coli BL21 (DE3), and performing induced expression on fusion protein connected with GST; carrying out enzyme digestion, and then using an anion exchange column and a gel column for further purifying to obtain the rbGrx with the purity of 98% or more. Then, culture is carried out under the crystallization conditions of pH being 4.5, 22% of PEG 3350 (W / V) and 0.1M of CH3COONa, so that a compound crystal of the rbGrx and glutathione (GSH) is obtained; the structure of the compound crystal is measured by an X-ray single-crystal diffraction method, so that important amino acid residues related to catalytic activity can be clearly distinguished, and the stability and enzyme activity are further regulated and controlled purposefully. The rbGrx also has high thioltransferase activity, and the enzyme specific activity is 300U / mg. The rbGrx can be applied to a catalytic thiol transfer reaction, and the crystal and structure of the rbGrx also have a practical value in the aspects of health care, food development, and the like.